Cargando…
Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
BACKGROUND: Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) represents the most common serious complication after endoscopic retrograde cholangiopancreatography (ERCP). Rectal non-steroidal anti-inflammatory drugs (NSAIDs) and pancreatic duct stenting (PDS) are the prophylacti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284647/ https://www.ncbi.nlm.nih.gov/pubmed/37351082 http://dx.doi.org/10.14740/gr1620 |
_version_ | 1785061447629275136 |
---|---|
author | Palomera-Tejeda, Emmanuel Shah, Mihir Prakash Attar, Bashar M. Shah, Hassam Sharma, Bharosa Oleas, Roberto Kotwal, Vikram Gandhi, Seema Mutneja, Hemant Raj |
author_facet | Palomera-Tejeda, Emmanuel Shah, Mihir Prakash Attar, Bashar M. Shah, Hassam Sharma, Bharosa Oleas, Roberto Kotwal, Vikram Gandhi, Seema Mutneja, Hemant Raj |
author_sort | Palomera-Tejeda, Emmanuel |
collection | PubMed |
description | BACKGROUND: Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) represents the most common serious complication after endoscopic retrograde cholangiopancreatography (ERCP). Rectal non-steroidal anti-inflammatory drugs (NSAIDs) and pancreatic duct stenting (PDS) are the prophylactic interventions with more evidence and efficacy; however, PEP still represents a significant source of morbidity, mortality, and economic burden. Chronic statin use has been proposed as a prophylactic method that could be cheap and relatively safe. However, the evidence is conflicting. We aimed to evaluate the impact of endoscopic and pharmacological interventions including chronic statin and aspirin use, on the development of PEP. METHODS: A retrospective cohort study evaluated consecutive patients undergoing ERCP at John H. Stroger, Jr. Hospital of Cook County in Chicago from January 2015 to March 2018. Univariate and multivariate analyses were performed using logistic regression. RESULTS: A total of 681 ERCPs were included in the study. Twelve (1.76%) developed PEP. Univariate, multivariate, and subgroup analyses did not show any association between chronic statin or aspirin use and PEP. PDS and rectal indomethacin were protective in patients undergoing pancreatic duct injection. Pancreatic duct injection, female sex, and younger age were associated with a higher risk. History of papillotomy was associated with lower risk only in the univariate analysis (all P values < 0.05). CONCLUSION: Chronic use of statins and aspirin appears to add no additional benefit to prevent ERCP pancreatitis. Rectal NSAIDs, and PDS after appropriate patient selection continue to be the main prophylactic measures. The lower incidence at our center compared with the reported data can be explained by the high rates of rectal indomethacin and PDS, the use of noninvasive diagnostic modalities for patient selection, and the expertise of the endoscopists. |
format | Online Article Text |
id | pubmed-10284647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102846472023-06-22 Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Palomera-Tejeda, Emmanuel Shah, Mihir Prakash Attar, Bashar M. Shah, Hassam Sharma, Bharosa Oleas, Roberto Kotwal, Vikram Gandhi, Seema Mutneja, Hemant Raj Gastroenterology Res Original Article BACKGROUND: Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) represents the most common serious complication after endoscopic retrograde cholangiopancreatography (ERCP). Rectal non-steroidal anti-inflammatory drugs (NSAIDs) and pancreatic duct stenting (PDS) are the prophylactic interventions with more evidence and efficacy; however, PEP still represents a significant source of morbidity, mortality, and economic burden. Chronic statin use has been proposed as a prophylactic method that could be cheap and relatively safe. However, the evidence is conflicting. We aimed to evaluate the impact of endoscopic and pharmacological interventions including chronic statin and aspirin use, on the development of PEP. METHODS: A retrospective cohort study evaluated consecutive patients undergoing ERCP at John H. Stroger, Jr. Hospital of Cook County in Chicago from January 2015 to March 2018. Univariate and multivariate analyses were performed using logistic regression. RESULTS: A total of 681 ERCPs were included in the study. Twelve (1.76%) developed PEP. Univariate, multivariate, and subgroup analyses did not show any association between chronic statin or aspirin use and PEP. PDS and rectal indomethacin were protective in patients undergoing pancreatic duct injection. Pancreatic duct injection, female sex, and younger age were associated with a higher risk. History of papillotomy was associated with lower risk only in the univariate analysis (all P values < 0.05). CONCLUSION: Chronic use of statins and aspirin appears to add no additional benefit to prevent ERCP pancreatitis. Rectal NSAIDs, and PDS after appropriate patient selection continue to be the main prophylactic measures. The lower incidence at our center compared with the reported data can be explained by the high rates of rectal indomethacin and PDS, the use of noninvasive diagnostic modalities for patient selection, and the expertise of the endoscopists. Elmer Press 2023-06 2023-06-11 /pmc/articles/PMC10284647/ /pubmed/37351082 http://dx.doi.org/10.14740/gr1620 Text en Copyright 2023, Palomera-Tejeda et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Palomera-Tejeda, Emmanuel Shah, Mihir Prakash Attar, Bashar M. Shah, Hassam Sharma, Bharosa Oleas, Roberto Kotwal, Vikram Gandhi, Seema Mutneja, Hemant Raj Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis |
title | Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis |
title_full | Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis |
title_fullStr | Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis |
title_full_unstemmed | Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis |
title_short | Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis |
title_sort | pharmacological and endoscopic interventions for prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284647/ https://www.ncbi.nlm.nih.gov/pubmed/37351082 http://dx.doi.org/10.14740/gr1620 |
work_keys_str_mv | AT palomeratejedaemmanuel pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis AT shahmihirprakash pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis AT attarbasharm pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis AT shahhassam pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis AT sharmabharosa pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis AT oleasroberto pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis AT kotwalvikram pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis AT gandhiseema pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis AT mutnejahemantraj pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis |